Latest News and Press Releases

Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer...

Vaughan, ON, March 26, 2026 (GLOBE NEWSWIRE) -- Ontario’s economy is facing serious challenges caused by difficult global headwinds. The Residential and Civil Construction Alliance of Ontario...

Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025

Last participant has been randomized and dosed in the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP)The study size was expanded to 183 participants due to patient and...

Rapid7 Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Oxford: Owner of Tommy Bahama, Lilly Pulitzer and Johnny Was Reports Fourth Quarter and Full-Year Fiscal 2025 Results

Spero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary tract infections (cUTI), including pyelonephritis in December 2025In February, Spero’s...

Rapid7 Acquires Kenzo Security to Accelerate Preemptive, AI-Powered Security Operations

SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a Marketing Authorization Application (MAA) to Brazil’s National Health...

WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to...